The Case for and Against eBay Inc. (EBAY)

eBay Inc. (EBAY) is an interesting player in the Services space, with a focus on Specialty Retail, Other. The stock has been active on the tape, currently trading at $40.29, down from yesterday’s close by -0.40%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

eBay Inc. (EBAY) currently trades with a market capitalization of $39.71 Billion. That value represents a market adjusting for revenues that have been growing by 16.37 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $2.37 Billion over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $0.51 on a per share basis this quarter. Perhaps, that suggests something about why 7.02% of the outstanding share supply is held by institutional investors.

Technical Analysis

It’s important to check the technicals to get a sense of how EBAY has been acting. Looking at the stock’s movement on the chart, eBay Inc. recorded a 52-week high of $46.99. It is now trading 6.7% off that level. The stock is trading $39.13 its 50-day moving average by -1.16%. The stock carved out a 52-week low down at $33.89.

In recent action, eBay Inc. (EBAY) has made a move of +4.65% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 14.04, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 3.17% with $933.31 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of EBAY.

Previous articleDrilling Down Into Hanesbrands Inc. (HBI)
Next articleJust the Facts on Acorda Therapeutics, Inc. (ACOR)